Identification of protein biomarkers to differentiate between gram-negative and gram-positive infections in adults suspected of sepsis
- PMID: 41239342
- PMCID: PMC12619434
- DOI: 10.1186/s12879-025-11973-5
Identification of protein biomarkers to differentiate between gram-negative and gram-positive infections in adults suspected of sepsis
Abstract
Background: Sepsis is mostly caused by bacterial infections and requires a prompt diagnosis. There is a need for improved diagnostics by differentiating between gram-negative and gram-positive bacterial infections.
Methods: The plasma levels of 285 unique proteins in patients with gram-negative infection (n = 154), gram-positive infection (n = 92), and in healthy controls (n = 35) were quantified using proximity extension assay. Three machine learning algorithms; random forest, recursive feature elimination, and adaptive least absolute shrinkage and selection operator (Lasso) were employed to identify discriminative proteins, with their effectiveness assessed using accuracy metrics. The selected proteins were further evaluated for their ability to differentiate between gram-negative and gram-positive infections through logistic regression and area under the receiver operating characteristic curve.
Results: We identified 55 discriminative proteins differentiating between gram-negative and gram-positive infections using the Lasso, the best performing algorithm. The discriminative proteins achieved AUROC values of 0.69 for gram-negative infections and 0.66 for gram-positive infections, both compared to the remaining groups, and 0.58 for differentiating between the two infection groups. Comparative statistical analysis revealed no significant differences in protein expression between gram-negative and gram-positive patients.
Conclusions: We identified 55 proteins with some discriminative potential between gram-negative and gram-positive infections. However, the overall predictive performance was low and did not exceed that of established single biomarkers. These findings highlight the challenges of applying a multimarker approach in infection classification and emphasize the need for further studies using larger and more diverse cohorts, as well as broader analytical methods, to explore their potential clinical utility.
Clinical trial: Not applicable.
Supplementary Information: The online version contains supplementary material available at 10.1186/s12879-025-11973-5.
Keywords: Biomarkers; Diagnostics; Gram-negative bacteria; Gram-positive bacteria; Machine learning; Proteomics; Sepsis.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The research received approval from the Regional Ethical Review Board of Gothenburg (376-11), and it exclusively involved individuals who provided their written informed consent. Consent for publication: Not applicable. Competing interests: AS declares stock ownership and is a board member of Iscaff Pharma, SiMSen Diagnostics, and Tulebovaasta. JB was employed by the company TATAA Biocenter AB. MIS, AKP, DT, AVM, and ME do not have any competing interests.
Figures
References
-
- World Health Organization. Improving the prevention, diagnosis and clinical management of sepsis. Report No.: a70/13. 2017, April, 13
-
- Irani-Shemirani M. Biomarkers approach in the diagnosis and prognosis of sepsis. Int J Public Health Res. 2022;12:1617–24 - DOI
LinkOut - more resources
Full Text Sources
